Trial of New NSAID MX-1094 as Arthritis Treatment Begins

A phase I safety trial of MX-1094, a nonsteroidal antiinflammatory drug, for the treatment of arthritis has begun in the Netherlands, according to Medinox, the drug's manufacturer.

"We are excited about moving forward into clinical development with this promising new compound," said Monte Lai, Medinox's President and CEO. "We believe that MX-1094 will meet the need for safer NSAIDs and has the potential to be a leading clinical therapy."

The randomized, double-blind, placebo-controlled, escalating single- and multiple-dose study also will evaluate the tolerability and pharmacokinetics of the drug in healthy volunteers.

The trial should be completed by the end of 2002.

Other sources: Medinox